Bladder cancer survival rates drop after shortage of crucial drug

Bladder cancer survival rates drop after shortage of crucial drug Bladder cancer survival rates have fallen due to a world-wide shortage of a crucial drug, figures suggest.

New Office for National Statistics data shows the chances of living five years beyond diagnosis dropped 2.5 per cent between 2016 and 2017 to 52.6 per cent.

It follows a period of limited supplies of Bacillus Calmette-Guerin, an immunotherapy that keeps the cancer at bay and prevents it from coming back. The Daily Telegraph